MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds received from
issuance of common stock...
$4,929K
Proceeds received from
notes payable
$2,250K
Proceeds received from
exercise of prefunded...
$30K
Net cash provided by
financing activities
$7,209K
Net increase
(decrease) in cash
$155K
Canceled cashflow
$7,054K
Forward Sales Contract
Expense
-$5,800K
Stock-based compensation
$1,496K
Due to related party
$750K
Other receivables
-$342K
Amortization of right-of-use
asset
$198K
Issuance of common stock
to consultant for...
$141K
Issuance of common stock
in connection with...
$69K
Depreciation and
amortization
$65K
Accounts payable and
accrued expenses
$60K
Impairment of right-of-use
asset
$33K
Accrued interest
expense
$22K
Other liabilities
$15K
Loss on disposal of
fixed assets
-$13K
Other non-current
assets
-$8K
Net increase
(decrease) in cash
$155K
Net cash used in
operating activities
-$7,017K
Net cash used in
investing activities
-$37K
Canceled cashflow
$9,012K
Net Income Loss
-$14,100K
Purchase of property and
equipment
$37K
Gains Losses On
Extinguishment Of Debt
$800K
Due from related
party
$750K
Prepaid expenses and
other current assets
$268K
Operating lease liability
-$208K
Back
Back
Cash Flow
source: myfinsight.com
Ernexa Therapeutics Inc. (ERNAW)
Ernexa Therapeutics Inc. (ERNAW)